Stemline Targeting cancer at its root
developing novel drugs that attack Cancer Stem Cells

For more information
on BPDCN, click here



The Company
Stemline Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing novel therapeutics that target both cancer stem cells (CSCs) and tumor bulk.
Clinical Trials
Cancer Stem Cells
Platform
Stemline Therapeutics has developed a Discovery Platform called StemScreen to identify novel compounds that target and kill CSCs.


News
&
Events
5/19/2016
SL-401 Phase 2 BPDCN Data Selected for Oral Presentation at ASCO & EHA Meeting
5/9/2016
Stemline Therapeutics Reports First Quarter 2016 Financial Results
5/3/2016
Stemline Therapeutics Clears First Cohort of Patients in Ongoing SL-801 Phase 1
Copyright 2016 - Stemline Therapeutics, Inc. All rights reserved
Stemline